GSK 以 1.4B 美元收购 Aiolos Bio，获得 AIO-001（一种潜在的哮喘治疗药物），进入 II 期临床开发。 GSK acquires Aiolos Bio for $1.4B, securing AIO-001, a potential asthma treatment, entering phase II clinical development.
英国制药公司 GSK 已完成对 Aiolos Bio 的收购，Aiolos Bio 是一家专注于呼吸和炎症疾病的临床阶段生物制药公司。 British pharmaceutical company, GSK, has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company specializing in respiratory and inflammatory conditions. 此次收购包括 AIO-001，这是一种长效抗胸腺基质淋巴细胞生成素单克隆抗体，即将进入治疗成年哮喘患者的 II 期临床开发。 The acquisition includes AIO-001, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody set to enter phase II clinical development for treating adult patients with asthma. 该交易价值高达 14 亿美元，其中葛兰素史克 (GSK) 预付款 10 亿美元，潜在里程碑付款高达 4 亿美元。 The deal is worth up to $1.4 billion, with GSK paying $1 billion upfront and up to $400 million in potential milestones.